IMED licenses technology from Medarex

Press release
March 4, 2008

IMED licenses technology from Medarex

LinkMed's portfolio company IMED AB has entered into an agreement with Medarex,
Inc. to enable IMED AB to develop and commercialize fully human monoclonal
antibodies that have been generated by IMED using Medarex's UltiMAb® technology.

This agreement expands rights previously granted by Medarex to IMED. IMED plans
to develop antibodies to a specific target identified by IMED for the treatment
of immune disorders and diseases related to deregulation of cell death, e.g.
transplantation and HIV.
 “We are pleased to enter this agreement with Medarex, a major player within the
field of antibody development,” said Lotta Ljungqvist, CEO of IMED AB. 
“Medarex's UltiMAb technology has generated numerous fully human antibodies that
are currently in human clinical trials.  We believe that using fully human
antibodies provides an advantage to us and could lead to the successful
development of antibody therapeutics.”

Under the terms of the agreement, IMED will be responsible for the development
and commercialization of the fully human antibody therapeutics. Medarex is
entitled to receive certain license fees and milestone payments as well as
royalties on commercial sales of products that may be developed under the
agreement.

IMED is focused on advancing its lead project in GVHD to block apoptosis using a
human monoclonal antibody generated by the use of Medarex's UltiMAb technology.
IMED is investing in its lead project, currently in a preclinical phase, and
readying it for advancement to the clinical phase. GVHD is a life threatening
complication after bone marrow or stem cell transplantation in which the new
transplant, i.e., the graft, attacks the patient, the host, resulting in a
systemic disease which affects primarily the skin, liver and gastrointestinal
tract. 

LinkMed owns 42.3 percent of IMED AB. 


For additional information please contact:
Ingemar Lagerlöf, CEO LinkMed +46 (08) 508 939 93